KYMR - Kymera Therapeutics, Inc.
NASDAQ
->
Healthcare
->
Biotechnology
Watertown,
United States
Type: Equity
KYMR price evolution
KYMR
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $73.45 | $99.33 | $115.78 | |
| Short term investments | $442.34 | $427.03 | $264.92 | |
| Net receivables | $1.32 | $1.7 | $2.03 | $15 |
| Inventory | ||||
| Total current assets | $568.72 | $525.41 | $537.25 | $405.32 |
| Long term investments | $192.44 | $224.39 | $61.43 | |
| Property, plant & equipment | $99.31 | $100.44 | $98.67 | $101.08 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $300.61 | $331 | $170.44 | |
| Total investments | $634.79 | $651.42 | $326.35 | |
| Total assets | $1034.84 | $826.02 | $868.25 | $575.76 |
| Current liabilities | ||||
| Accounts payable | $6.49 | $6.51 | $6.81 | $7.08 |
| Deferred revenue | $22.45 | $46.39 | $54.65 | |
| Short long term debt | $12.42 | $9.89 | $6.34 | |
| Total current liabilities | $66.53 | $62.14 | $56.14 | $85.69 |
| Long term debt | $1.74 | $75.77 | $77.13 | $78.33 |
| Total noncurrent liabilities | $78.95 | $100.91 | $95.1 | |
| Total debt | $88.18 | $87.02 | $84.67 | |
| Total liabilities | $141.91 | $141.1 | $157.05 | $180.79 |
| Shareholders' equity | ||||
| Retained earnings | -$683.86 | -$621.37 | -$579.31 | -$530.75 |
| Other shareholder equity | $1.93 | -$2.1 | -$1.78 | -$0.55 |
| Total shareholder equity | $684.92 | $711.2 | $394.97 | |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $115.78 | $74.53 | $54.09 | $32.59 |
| Short term investments | $264.92 | $338.77 | $394.44 | $265.2 |
| Net receivables | $15 | $2.54 | $0.14 | $0.58 |
| Inventory | ||||
| Total current assets | $405.32 | $419.42 | $451.27 | $302.34 |
| Long term investments | $61.43 | $152.33 | $125.19 | $162.53 |
| Property, plant & equipment | $101.08 | $22.24 | $21.31 | $20.69 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $170.44 | $183.72 | $154.63 | $184.84 |
| Total investments | $326.35 | $491.1 | $519.63 | $427.73 |
| Total assets | $575.76 | $603.13 | $605.9 | $487.18 |
| Current liabilities | ||||
| Accounts payable | $7.08 | $4.33 | $4 | $4.37 |
| Deferred revenue | $54.65 | $63.26 | $101.03 | $170.39 |
| Short long term debt | $6.34 | $3.94 | $3.6 | $3.26 |
| Total current liabilities | $85.69 | $71.34 | $92.54 | $110.62 |
| Long term debt | $78.33 | $1.25 | $14.36 | $14.73 |
| Total noncurrent liabilities | $95.1 | $41.64 | $53.73 | $92.67 |
| Total debt | $84.67 | $17.34 | $17.96 | $17.99 |
| Total liabilities | $180.79 | $112.98 | $146.27 | $203.29 |
| Shareholders' equity | ||||
| Retained earnings | -$530.75 | -$383.79 | -$228.98 | -$128.76 |
| Other shareholder equity | -$0.55 | -$4.95 | -$0.66 | -$0.13 |
| Total shareholder equity | $394.97 | $490.15 | $459.64 | $283.89 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $3.74 | $25.65 | $10.29 | $47.88 |
| Cost of revenue | ||||
| Gross Profit | $25.65 | $10.29 | $47.88 | |
| Operating activities | ||||
| Research & development | $59.2 | $48.82 | $52.97 | |
| Selling, general & administrative | $17.37 | $14.37 | $14.23 | |
| Total operating expenses | $75.86 | $76.58 | $68.12 | $67.2 |
| Operating income | -$50.92 | -$57.83 | -$19.31 | |
| Income from continuing operations | ||||
| EBIT | -$42 | -$48.49 | -$14.32 | |
| Income tax expense | ||||
| Interest expense | $9.64 | $0.06 | $0.07 | $0.05 |
| Net income | ||||
| Net income | -$62.49 | -$42.06 | -$48.56 | -$14.37 |
| Income (for common shares) | -$42.06 | -$48.56 | -$14.37 | |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $78.59 | $34.03 | ||
| Cost of revenue | ||||
| Gross Profit | $78.59 | $34.03 | ||
| Operating activities | ||||
| Research & development | $189.08 | $164.25 | $137.02 | $62.1 |
| Selling, general & administrative | $55.04 | $43.83 | $36.34 | $18.23 |
| Total operating expenses | $244.12 | $208.08 | $173.36 | $80.34 |
| Operating income | -$165.53 | -$208.08 | -$173.36 | -$46.3 |
| Income from continuing operations | ||||
| EBIT | -$146.77 | -$154.63 | -$100.04 | -$45.48 |
| Income tax expense | ||||
| Interest expense | $0.2 | $0.18 | $0.17 | $0.12 |
| Net income | ||||
| Net income | -$146.96 | -$154.81 | -$100.22 | -$45.59 |
| Income (for common shares) | -$146.96 | -$154.81 | -$100.22 | -$45.59 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Net income | -$42.06 | -$48.56 | -$14.37 | |
| Operating activities | ||||
| Depreciation | $1.94 | $1.46 | $0.89 | |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $14.34 | $11.97 | $10.9 | |
| Total cash flows from operations | -$42.94 | -$39.59 | $8.04 | |
| Investing activities | ||||
| Capital expenditures | -$4.69 | -$7.4 | -$11.63 | |
| Investments | $20.33 | -$323.2 | $30.58 | |
| Total cash flows from investing | -$472.64 | $15.64 | -$330.61 | $18.95 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $1.76 | $354.05 | $1.01 | |
| Net borrowings | -$0.35 | -$0.29 | $0.93 | |
| Total cash flows from financing | $606.09 | $1.41 | $353.76 | $1.93 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | $0.72 | -$25.88 | -$16.44 | $28.93 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | -$146.96 | -$154.81 | -$100.22 | -$45.59 |
| Operating activities | ||||
| Depreciation | $3.56 | $2.98 | $2.4 | $1.76 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $43.12 | $35.48 | $24.97 | $5.19 |
| Total cash flows from operations | -$102.83 | -$153.09 | -$128.95 | $88.13 |
| Investing activities | ||||
| Capital expenditures | -$34.48 | -$2.84 | -$1.6 | -$9.1 |
| Investments | $174.37 | $23.36 | -$98.24 | -$413.49 |
| Total cash flows from investing | $139.89 | $20.52 | -$99.83 | -$422.59 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $4.27 | $154.13 | $251.13 | $196.84 |
| Net borrowings | -$0.08 | -$1.13 | -$0.85 | -$0.55 |
| Total cash flows from financing | $4.19 | $153 | $250.28 | $289.26 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | $41.25 | $20.43 | $21.5 | -$45.2 |
News
Fundamentals
| Market cap | $3.04B |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 64.75M |
| Revenue | $87.56M |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | -$167.47M |
| Revenue Q/Q | InfinityT% |
| Revenue Y/Y | N/A |
| P/E ratio | -18.18 |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | 34.77 |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | -$2.59 |
|---|---|
| ROA | -20.27% |
| ROE | N/A |
| Debt/Equity | 0.46 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 8.55 |
| Quick ratio | N/A |